---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-003165"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2022-01-06T23:59:59+00:00"
generated_at: "2026-06-27T20:18:42.726186+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Aligos halts ALG-010133 development after Phase 1 data show no meaningful HBsAg reduction

## Summary
- Halted development of STOPS drug candidate ALG-010133 for chronic hepatitis B.
- Phase 1 study showed no meaningful HBsAg reduction at projected efficacious dose of 400 mg.
- Higher doses up to 600 mg unlikely to reach 1 log10 IU/mL HBsAg reduction threshold.
- No dose-limiting safety findings; decision made jointly with Study Review Committee.

## SEC filing metadata
- accession: 0001193125-22-003165
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2022-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000119312522003165/0001193125-22-003165-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000119312522003165/d288360d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-003165
- JSON: https://secwatch.observer/filing/0001193125-22-003165.json
- Plain text: https://secwatch.observer/filing/0001193125-22-003165.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.